CSIMarket
 
Icon Plc  (NASDAQ: ICLR)
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $164.9900 $-5.03 -2.958%
Day's High: $170.41000366210938 Week Perf: -2.32 %
Day's Low: $ 163.57 30 Day Perf: 0.87 %
Volume (M): 707,457 52 Wk High: $ 203.91
Volume (M$): $ 0 52 Wk Avg: $153.28
Open: $169.91 52 Wk Low: $66.57



 Market Capitalization (Millions $) 13,029
 Shares Outstanding (Millions) 79
 Employees 40,100
 Revenues (TTM) (Millions $) 8,251
 Net Income (TTM) (Millions $) 229
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Icon Plc is a global provider of clinical trials and consulting services that has been in operation since 1990. The company is headquartered in Dublin, Ireland, and operates multiple offices and laboratories across North America, Europe, and Asia-Pacific. Icon Plc is well known for its expertise in drug development, innovative technology solutions, and analytical and laboratory services.

Clinical trials are the primary focus of Icon Plc. The company offers drug development, clinical and medical affairs, patient and site engagement, and data management services to support various stages of clinical trials. Icon Plc has experience in numerous therapeutic areas, such as oncology, neurology, cardiovascular diseases, infectious diseases, and immunology, among others. The company's main goal is to accelerate clinical development timelines, reduce operational costs and provide superior data integrity to support sponsors' and healthcare providers' decisions.

Icon Plc also provides consulting services, including regulatory and safety consulting, which involves providing support on drug regulatory compliance; clinical feasibility consulting; and market access consulting, helping clients get their products to market faster. The company has global, regional and country-specific regulatory experts on its team who have extensive past experience in dealing with regulatory bodies worldwide.

Icon Plc's use of cutting-edge technology has contributed to its success at revolutionizing how clinical trials are conducted. The company has its own proprietary platforms, tools, and innovative technologies such as Firecrest (an e-learning platform for clinical trial management), IConnect (an intelligent patient recruitment tool) and Symphony (a clinical data management platform). Icon Plc has also implemented artificial intelligence, machine learning, and natural language processing, among other technologies, to help automate labor-intensive clinical trial processes, making more accurate and timely decisions, and saving clientse time and money.

Icon Plc's advanced analytical and laboratory services have further enhanced its position as a leading provider of clinical trials. Its labs conduct precision medicine biomarker assays, genomics, proteomics, pharmacology, and biomarker immunoassays. Icon Plc has expertise in analyzing complex molecules such as biosimilars and designing customized solutions to accommodate regulatory requirements.

In summary, Icon Plc is a global leader in clinical trials and consulting services, well-strategized to provide full-service offerings from discovery to commercialization. With its proprietary platforms and cutting-edge technologies, Icon Plc has been able to offer meticulous data-driven solutions to clients from diverse therapeutic areas. The company is committed to accelerating drug development timelines, minimizing operational costs, and providing high-quality data with its extensive worldwide team of experts.


   Company Address: South County Business Park Dublin 18 0
   Company Phone Number: 291-2000   Stock Exchange / Ticker: NASDAQ ICLR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
MEDP   -4.2%    
CERT        4.15% 
SLP      0% 
• View Complete Report
   



Announcement

Legal Action Casts Shadow Over ICONs Investor Relations,

Published Mon, Apr 7 2025 6:23 PM UTC

Investors Allege Misconduct in Class Action Lawsuit Against ICON Public Limited Company By April 8, 2025In a significant legal development, ICON Public Limited Company (NASDAQ: ICLR), a prominent player in the clinical research field, finds itself embroiled in a class action securities lawsuit. The legal proceedings, initiated by the law firm Levi & Korsinsky, LLP, are aim...

Announcement

Investors on Alert ICON plc Faces Securities Class Action with April 11 Deadline Looming

Published Sat, Mar 29 2025 8:38 PM UTC

As the ongoing landscape of investment litigation unfolds, the Rosen Law Firm, a respected name in the realm of investor rights, has issued a critical reminder for shareholders of ICON plc (NASDAQ: ICLR). The firm is calling attention to a pending securities class action that targets purchasers of ordinary shares during a specific timeframe from July 27, 2023, to October 2...

Announcement

Caught in the Crossfire ICON PLC Investors Rally for Justice in Class Action Suit,

Published Mon, Feb 24 2025 6:09 PM UTC

In the ever-volatile world of financial markets, the unexpected can turn a promising investment into a disheartening experience in the blink of an eye. Recent developments surrounding ICON Public Limited Company (NASDAQ: ICLR) have left many investors feeling the sting of losses, and now, a class action lawsuit is casting a spotlight on potential recovery options.As of Febru...

Business Update

ICON Synchronizing Clinical Research Excellence with Corporate Responsibility in 2024

Published Wed, Jul 10 2024 11:54 AM UTC

ICON: Leading the Charge in Clinical Research and Corporate Social Responsibility DUBLIN, March 2024 In a series of significant recognitions, ICON plc (NASDAQ: ICLR) has solidified its standing as not only a leader in clinical research but also as a paragon of corporate responsibility. This dual recognition underscores the company s commitment to excellence within the ph...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 25.52
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1.58
Price to Sales (Expected) -
Price to Book 1.42
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.2
Working Capital Ratio 1.08
Leverage Ratio (MRQ) 0.77
Total Debt to Equity 0.43
Interest Coverage (TTM) -
Debt Coverage (TTM) 0.17

Per Share Current
Earnings (TTM) 6.47 $
Revenues (TTM) 104.49 $
Cash Flow (TTM) -
Cash 8.23 $
Book Value 116.42 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 205,769
Net Income per Employee (TTM) 5,719
Receivable Turnover Ratio (TTM) 5.88
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.5

Profitability Ratios Current
Gross Margin (MRQ) 26.37 %
Operating Margin (MRQ) 5.37 %
Net Margin (MRQ) -1.33 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) 0.61 %

Management Effectiveness Current
Return On Assets (TTM) 1.4 %
Return On Investment (TTM) 1.7 %
Return On Equity (TTM) 2.47 %
Dividend Yield -
Pay out Ratio (TTM) -



Icon Plc's Segments
Top client    6.98 % of total Revenue
Clients 2-5    17.82 % of total Revenue
Clients 6-10    14.12 % of total Revenue
Clients 11-25    25.11 % of total Revenue
Other    35.97 % of total Revenue
Ireland    38.58 % of total Revenue
Rest of Europe    19.28 % of total Revenue
U S    30.6 % of total Revenue
Rest of World    11.54 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.